• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

135062-02-1 (Repaglinide)



Repaglinide Repaglinide
Name Repaglinide
Formula C27H36N2O4
MW 452.59
CAS No. 135062-02-1
Smiles O=C(CC1=CC(OCC)=C(C(O)=O)C=C1)N[[email protected]@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3
Synonyms (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; Novonorm; Prandin; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
InChI InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1


Repaglinide(AG-EE 623ZW) is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes.

Background Information

Repaglinide is an antidiabetic drug. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. ......by BOC Sciences
Repaglinide(AG-EE 623ZW) is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes. IC50 value: Target: Repaglinide is very rapidly absorbed (tmax less than 1 hour) with a t? of less than one hour. Furthermore, repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes. ......by MedChemexpress Co., Ltd.
Repaglinide is a potassium channel blocker, which lowers blood glucose by stimulating the release of insulin from the pancreas, used the treatment of type II diabetes. ......by Selleck Chemicals LLC
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. ......by Target Molecule Corp.

Protocol(Only for Reference)

Cell Experiment

Animal Experiment


Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000022576

Storage condition


DMSO >80 mg/ml Ethanol > 80 mg/ml by MedChemexpress Co., Ltd.
(25°C) * In vitro DMSO 91 mg/mL (201.06 mM); Ethanol91 mg/mL (201.06 mM); Water<1 mg/mL (<1 mM) by Selleck Chemicals LLC

Mechanism and Indication


Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Repaglinide Novo Nordisk A/S Non-insulin dependent diabetes 2002/7/31 2003/2/28 Phase 4 Clinical
Repaglinide Merck & Co Inc Non-insulin dependent diabetes 2012/11/30 2015/5/31 Phase 4 Clinical
Repaglinide Novo Nordisk A/S Non-insulin dependent diabetes 2002/4/30 2003/3/31 Phase 4 Clinical
Repaglinide Novo Nordisk A/S Non-insulin dependent diabetes 2001/11/30 2003/3/31 Phase 4 Clinical
Repaglinide Novo Nordisk A/S Non-insulin dependent diabetes 2002/3/31 2004/10/31 Phase 4 Clinical
Repaglinide - Launched

Safety Data of Repaglinide

RTECS : 000000033825
WGKGermany : 2

Spectral Information


Suppliers List

Company Price and Availability Country/Region
Abcam 50mg/USD139() USA
Aladdin China
AnHui HaiKang Pharmaceutical Co., Ltd. China
Anhui Lianchuang Pharmaceutical Chemistry Co., Ltd. China
Asia Talent Chemical Limited China
BOC Sciences
Bengbu Nako Chemical Co., Ltd. China
Epoch Biosciences (Shenzhen) Co., Ltd CHINA
Loudi Xinjiyuan Chemistry Co., Ltd. China
MedChemexpress Co., Ltd. 50mg/USD55(In stock);100mg/USD99(In stock) USA
Pharmaxyn Laboratories Ltd. China
Santa Cruz Biotechnology, Inc. 100mg/USD126() USA
Selleck Chemicals LLC 10mM/1mLIn DMSO/USD90(In stock);10mM(in 1mL DMSO)/USD90(in 1mL DMSO);50mg/USD97(In stock) USA
Shanghai Haoyuan Chemexpress Co., Ltd. 50mg/USD55(In stock);100mg/USD99(In stock) China
Target Molecule Corp. 2mg/USD20();10mg/USD65();50mg/USD135();200mg/USD256() USA
Tocris Bioscience Inc. 50mg/USD135() USA
Tokyo Chemical Industry Co., Ltd. 200mg/USD108() Japan

Related Products

Other Forms of 135062-02-1

Name CAS No Formula MW
Repaglinide (D5) 1217709-85-7 C27H31D5N2O4 457.62

Recommended Compounds in Others

Name CAS No Formula MW
(R)-(+)-Etomoxir (sodium salt) 828934-41-4 C15H18ClNaO4 320.74
Dictamine 484-29-7 C12H9NO2 199.21
Liothyronine (sodium) 55-06-1 C15H11I3NNaO4 672.96
Afobazole (hydrochloride) 173352-39-1 C15H22ClN3O2S 343.87
FPH2 957485-64-2 C14H16ClN5O2S 353.83
α-Tocopherol (phosphate) 38976-17-9 C29H51O5P 510.69
BAMB-4 891025-25-5 C15H12N2O2 252.27
LDN-27219 312946-37-5 C20H16N4O2S2 408.5
ISO-1 478336-92-4 C12H13NO4 235.24
Aurothioglucose 12192-57-3 C6H11AuO5S 392.18
Oxybenzone 131-57-7 C14H12O3 228.24
ITX3 347323-96-0 C22H17N3OS 371.45
Cardiogreen 3599-32-4 C43H47N2NaO6S2 774.96
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 465.34
INH1 313553-47-8 C18H16N2OS 308.4
PF6-AM 1268491-69-5 C33H31BO12 630.4
XEN445 1515856-92-4 C18H17F3N2O3 366.33
Methyl N-ethyl-N-4-(5-nitro-2,1-benzisothiazol-3-yl)azophenyl-alaninate 52239-04-0 C19H19N5O4S 413.45
1,4-bis(Butylamino)anthraquinone 17354-14-2 C22H26N2O2 350.45
CID 797718 370586-05-3 C12H11NO3 217.22

Recommended Compounds in Same Indication

Name CAS No Formula MW
Glibenclamide 10238-21-8 C23H28ClN3O5S 494.0
Mitiglinide (Calcium) 145525-41-3 C38H50CaN2O7 686.89
Teneligliptin 760937-92-6 C22H30N6OS 426.58
Empagliflozin 864070-44-0 C23H27ClO7 450.91
MK 0893 870823-12-4 C32H27Cl2N3O4 588.48
Canagliflozin 842133-18-0 C24H25FO5S 444.52
Manidipine (dihydrochloride) 89226-75-5 C35H40Cl2N4O6 683.62
Teneligliptin (hydrobromide) 906093-29-6 C44H65Br5N12O2S2 1257.72
Exendin-4 (Acetate) 914454-01-6 C186H286N50O62S 4246.62
Trelagliptin 865759-25-7 C18H20FN5O2 357.38
Linagliptin 668270-12-0 C25H28N8O2 472.54
Bardoxolone (methyl) 218600-53-4 C32H43NO4 505.69
Saxagliptin 361442-04-8 C18H25N3O2 315.41
Alogliptin 850649-61-5 C18H21N5O2 339.39
Alogliptin (Benzoate) 850649-62-6 C25H27N5O4 461.51
Aleglitazar 475479-34-6 C24H23NO5S 437.51
Imeglimin (hydrochloride) 775351-61-6 C6H14ClN5 191.66
Imeglimin 775351-65-0 C6H13N5 155.2
Balaglitazone 199113-98-9 C20H17N3O4S 395.43
Vildagliptin 274901-16-5 C17H25N3O2 303.4

Route of Synthesis




More Information


Tags: buy 135062-02-1 IC50 | 135062-02-1 price | 135062-02-1 cost | 135062-02-1 solubility | 135062-02-1 purchase | 135062-02-1 manufacturer | 135062-02-1 research buy | 135062-02-1 order | 135062-02-1 MSDS | 135062-02-1 chemical structure | 135062-02-1 Storage condition | 135062-02-1 molecular weight | 135062-02-1 mw | 135062-02-1 datasheet | 135062-02-1 supplier | 135062-02-1 cell line | 135062-02-1 NMR | 135062-02-1 MS | 135062-02-1 IR | 135062-02-1 solubility | 135062-02-1 Safe information | 135062-02-1 Qc and Spectral Information | 135062-02-1 Clinical Information | 135062-02-1 Clinical Trial | 135062-02-1 Route of Synthesis | 135062-02-1 storage condition | 135062-02-1 diseases and conditions | 135062-02-1 flash point | 135062-02-1 boiling point | 135062-02-1 melting point | 135062-02-1 storage condition | 135062-02-1 brand